Skip to content

Clinical trials

Phase 1/2 Recurrence trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Recurrence Phase: Phase 1/2 Clear all

399 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20007
20011
20035
20045
20058
20067
20075
200812
20095
201013
201116
201212
201312
201416
201513
201621
201721
201814
201918
202022
202123
202222
202328
202429
202528
202631

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed109
Recruiting89
Terminated73
Unknown status49
Not yet recruiting29
Active, not recruiting29
Withdrawn18
Suspended3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center11
Beijing Biotech8
Memorial Sloan Kettering Cancer Center8
Chinese PLA General Hospital6
Sun Yat-sen University6
Fred Hutchinson Cancer Center5
National Cancer Institute (NCI)5
Princess Maxima Center for Pediatric Oncology5
Regeneron Pharmaceuticals5
Therapeutic Advances in Childhood Leukemia Consortium5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Recurrence399
Multiple Myeloma62
Lymphoma50
Leukemia, Myeloid, Acute47
Neoplasms45
Leukemia36
Precursor Cell Lymphoblastic Leukemia-Lymphoma33
Lymphoma, Large B-Cell, Diffuse31
Lymphoma, Non-Hodgkin31
Neoplasm Metastasis30

Trials

Showing 26 to 50 of 399. Each trial links to its page on Pharma Observatory.

299 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.